Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

NEW YORK--(BUSINESS WIRE)--Wolters Kluwer, a global leader in professional information, software solutions and services, today announced the launch of a new report Paving the Way to Integrated ...

Wolters Kluwer, a global leader in professional information, software solutions and services, today announced the launch of a new report Paving the Way to Integrated Assurance: A Proactive ...

NEW YORK–(BUSINESS WIRE)–Wolters Kluwer, a global leader in professional information, software solutions and services, today announced the launch of a new report Paving the Way to Integrated Assurance ...

The journal’s editorial board includes multiple scientists, such as Trump health nominees Jay Bhattacharya and Marty Makary, ...

“We are excited for the additional services and technology that Wolters Kluwer can bring to RASi clients.” For RASi customers, this acquisition will ensure continued superior service as well ...

Whether the large effect size of endovascular thrombectomy (EVT) for stroke due to large-vessel occlusion applies to stroke due to medium-vessel occlusion is unclear. In a multicenter, prospective ...

Few procedures have gone through a decade of practice-changing clinical trials as impressive as thrombectomy for stroke. Beginning in 2015 with multiple trials showing a benefit with thrombectomy ...

Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...

Familial HLH is a success story in modern medicine. Initially a disease that ... to be 4.2 cases per 1 million population in 2018 in England. 15 The annual incidence of HLH associated with cancer ...